理学療法ジャーナル55巻11号

2021年11月発行

特集 パーキンソン病の最新知見と効果的な理学療法

パーキンソン病の最新治療

著者： 波田野琢¹ 服部信孝¹

所属機関： ¹順天堂大学大学院医学研究科神経学

ページ範囲：P.1172 - P.1181

Point

●パーキンソン病の薬物治療の中心はL-ドパ製剤である

●ドパミン受容体作動薬はL-ドパ製剤と比較して安定したドパミン刺激をするが，衝動制御障害，睡眠障害，精神症状の副作用に注意が必要である

●進行期パーキンソン病で経口治療が困難な場合，デバイスを用いた治療（脳深部刺激療法，L-ドパ持続経腸療法など）が症状緩和に役立つ

参考文献

1）Bloem BR, et al：Parkinson's disease. Lancet 2021；397：2284-2303

2）難病情報センター：特定医療費（指定難病）受給者証所持者数．https://www.nanbyou.or.jp/entry/5354（2021年7月29日閲覧）

3）Dorsey ER, et al：The Parkinson pandemic-a call to action. JAMA Neurol 2018；75：9-10

4）Connolly BS, et al：Pharmacological treatment of Parkinson disease：a review. JAMA 2014；311：1670-1683

5）Olanow CW, et al：Continuous dopamine-receptor treatment of Parkinson's disease：scientific rationale and clinical implications. Lancet Neurol 2006；5：677-687

6）Dickson DW, et al：Neuropathological assessment of Parkinson's disease：refining the diagnostic criteria. Lancet Neurol 2009；8：1150-1157

7）Fahn S, et al：Levodopa and the progression of Parkinson's disease. N Engl J Med 2004；351：2498-2508

8）Parkinson Study Group：Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993；328：176-183

9）Olanow CW, et al：A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009；361：1268-1278

10）Schapira AH, et al：Pramipexole in patients with early Parkinson's disease（PROUD）：a randomised delayed-start trial. Lancet Neurol 2013；12：747-755

11）日本神経学会（監），「パーキンソン病診療ガイドライン」作成委員会（編）：パーキンソン病診療ガイドライン2018．医学書院，2018

12）Camargo SM, et al：The molecular mechanism of intestinal levodopa absorption and its possible implications for the treatment of Parkinson's disease. J Pharmacol Exp Ther 2014；351：114-123

13）Giovannoni G, et al：Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000；68：423-428

14）Antonini A, et al：A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. Lancet Neurol 2009；8：929-937

15）Corvol JC, et al：Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology 2018；91：e189-e201

16）Barone P, et al：Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease：a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010；9：573-580

17）Rabinak CA, et al：Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 2010；67：58-63

18）Group PDMC, Gray R, et al：Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease（PD MED）：a large, open-label, pragmatic randomised trial. Lancet 2014；384：1196-1205

19）Calabresi P, et al：Levodopa-induced dyskinesias in patients with Parkinson's disease：filling the bench-to-bedside gap. Lancet Neurol 2010；9：1106-1117

20）Ferreira JJ, et al：Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations：a randomised, double-blind, controlled trial. Lancet Neurol 2016；15：154-165

21）Lees AJ, et al：Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations：a randomized clinical trial. JAMA Neurol 2017；74：197-206

22）Trenkwalder C, et al：Rotigotine effects on early morning motor function and sleep in Parkinson's disease：a double-blind, randomized, placebo-controlled study（RECOVER）. Mov Disord 2011；26：90-99

23）Ray Chaudhuri K, et al：Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced Parkinson's disease. Eur J Neurol 2012；19：105-113

24）Bhidayasiri R, et al：Getting a good night sleep? The importance of recognizing and treating nocturnal hypokinesia in Parkinson's disease. Parkinsonism Relat Disord 2018；50：10-18

25）Hattori N, et al：Ropinirole patch versus placebo, ropinirole extended-release tablet in advanced Parkinson's disease. Mov Disord 2020；35：1565-1573

26）Borgohain R, et al：Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations. Mov Disord 2014；29：229-237

27）Schapira AH, et al：Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations：a randomized clinical trial. JAMA Neurol 2017；74：216-224

28）Cattaneo C, et al：Effects of safinamide on pain in fluctuating Parkinson's disease patients：a post-hoc analysis. J Parkinsons Dis 2017；7：95-101

29）Murata M, et al：Japan Zonisamide on PDSG. Zonisamide improves motor function in Parkinson disease：a randomized, double-blind study. Neurology 2007；68：45-50

30）Murata M, et al：Zonisamide improves wearing-off in Parkinson's disease：a randomized, double-blind study. Mov Disord 2015；30：1343-1350

31）Murata M, et al：Adjunct zonisamide to levodopa for DLB parkinsonism：a randomized double-blind phase 2 study. Neurology 2018；90：e664-e672

32）Murata M, et al：Effect of zonisamide on parkinsonism in patients with dementia with Lewy bodies：a phase 3 randomized clinical trial. Parkinsonism Relat Disord 2020；76：91-97

33）Mizuno Y, Japanese Istradefylline Study Group, et al：Clinical efficacy of istradefylline（KW-6002）in Parkinson's disease：a randomized, controlled study. Mov Disord 2010；25：1437-1443

34）Mizuno Y, Japanese Istradefylline Study Group, et al：Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease. Mov Disord 2013；28：1138-1141

35）Thomas A, et al：Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry 2004；75：141-143

36）Ory-Magne F, et al：Withdrawing amantadine in dyskinetic patients with Parkinson disease：the AMANDYSK trial. Neurology 2014；82：300-307

37）Hattori N, et al 6500-004 Study Group：Sustained efficacy of apomorphine in Japanese patients with advanced Parkinson's disease. Parkinsonism Relat Disord 2014；20：819-823

38）Okun MS：Deep-brain stimulation for Parkinson's disease. N Engl J Med 2012；367：1529-1538

39）Elias WJ, et al：A randomized trial of focused ultrasound thalamotomy for essential tremor. N Engl J Med 2016；375：730-739

40）Eisenberg HM, et al：MR-guided focused ultrasound pallidotomy for Parkinson's disease：safety and feasibility. J Neurosurg 2020：1-7. doi：10.3171/2020.6.JNS192773

41）Martinez-Fernandez R, et al：Randomized trial of focused ultrasound subthalamotomy for Parkinson's disease. N Engl J Med 2020；383：2501-2513

42）Olanow CW, et al：Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease：a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 2014；13：141-149

43）Liu XD, et al：Comparison between levodopa-carbidopa intestinal gel infusion and subthalamic nucleus deep-brain stimulation for advanced Parkinson's disease：a systematic review and meta-analysis. Front Neurol 2019；10：934. doi：10.3389/fneur.2019.00934. eCollection 2019